RSSDI Repository, Complications of Diabetes Demonstration RSSDI Repository, Complications of Diabetes Demonstration

Have a Question?

If you have any question you can ask below or enter what you are looking for!

  • Home/
  • Article /
  • Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial.

Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial.

Add to Collection
2020 Jun RCTs Fist_Author_Year_PM

Full Author : ['Blonde, Lawrence', 'Belousova, Lidia', 'Fainberg, Udi', 'Garcia-Hernandez, Pedro A', 'Jain, Sunil M', 'Kaltoft, Margit S', 'Mosenzon, Ofri', 'Nafach, Jalal', 'Palle, Mads Sundby', 'Rea, Rosangela']
Journal Title : Diabetes, obesity & metabolism
Chapter : Section3
Journal Year : 2020
Cited by : Not Available

AIM: To compare the effect of liraglutide or placebo added on to sodium-glucose co-transporter-2 inhibitor (SGLT2i) +/- metformin on glycaemic control in patients with type 2 diabetes. MATERIALS AND METHODS: Patients with type 2 diabetes on a stable SGLT2.....

Keywords : ["randomize doubleblind placebocontrolle trial", "inadequately control type diabetes", "sodiumglucose inhibitor", "patient", "liraglutide", "addon"]